New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...

A new case series published in JAMA Ophthalmology by R. Christopher Bowen from the Department of Ophthalmology, Feinberg ...

The meta-analysis identified a significant association between treatment with semaglutide and risk for NAION (OR, 3.92; 95% ...

Researchers have found in a new study that personal wealth is strongly associated with outcomes 12–18 months after a new ...

JAMA Ophthalmology (formerly Archives of Ophthalmology) is a monthly professional medical journal published by the American Medical Association. Archives of Ophthalmology publishes peer-reviewed, ...

Please provide your email address to receive an email when new articles are posted on . A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential ...

A compounded form of imiquimod, a topical immune response modifier, showed promise as a treatment for ocular surface ...

HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology ...

Chicago, June 30, 2023 – JAMA and the journals in the JAMA Network are among the highest in their respective fields, according to the 2023 update to Clarivate’s annual Journal Citation Reports (JCR). ...

Among 34,239 matched pairs, the risk of incident nonproliferative diabetic retinopathy was not different between patients taking empagliflozin or DPP-4 inhibitors (HR 1.04, 95% CI 0.94-1.15) over a ...